FrancophonIA/ELRC3.0 huggingface dataset:
English: In the first main study (in patients with acute coronary syndrome), 9.3% of the patients taking Brilique had another heart attack, stroke or died from a cardiovascular disease compared with 10.9% of patients taking clopidogrel.
Slovenian: V prvi glavni študiji (pri bolnikih z akutnim koronarnim sindromom) je 9,3 % bolnikov, ki so jemali zdravilo Brilique, doživelo še en srčni infarkt ali kap ali pa so umrli zaradi srčno-žilne bolezni, v primerjavi z 10,9 % bolnikov, ki so jemali klopidogrel.
English: Brilique is also used in adults who had a heart attack a year or more ago and are at a high risk of an atherothrombotic event.
Slovenian: Zdravilo Brilique se uporablja tudi pri odraslih, ki so doživeli srčni infarkt pred enim letom ali več, in pri katerih obstaja veliko tveganje za nastanek aterotrombotičnih dogodkov.
English: The CHMP considered that in patients with acute coronary artery syndrome, Brilique at a dose of 90 mg twice daily and given with aspirin, reduces the risk of atherothrombotic events such as heart attack, stroke and death from a cardiovascular event.
Slovenian: Menil je, da pri bolnikih z akutnim koronarnim sindromom zdravilo Brilique v 90-miligramskem odmerku, vzetem dvakrat na dan skupaj z aspirinom, zmanjša tveganje za nastanek aterotrombotičnih dogodkov, kot so srčni infarkt, kap in smrt zaradi srčno-žilne bolezni.
English: The active substance in Brilique, ticagrelor, is an inhibitor of platelet aggregation.
Slovenian: Zdravilna učinkovina zdravila Brilique, ticagrelor, je zaviralec agregacije trombocitov.
English: Brilique was compared with clopidogrel (another inhibitor of platelet aggregation) in a main study involving over 18,000 adults who had had a heart attack or had unstable angina.
Slovenian: Zdravilo Brilique so primerjali s klopidogrelom (drugim zaviralcem agregacije trombocitov) v glavni študiji, v katero je bilo vključenih več kot 18 000 odraslih z nestabilno angino pektoris ali po srčnem infarktu.
English: Patients took Brilique twice a day in a dose of either 60 mg or 90 mg.
Slovenian: Bolniki so zdravilo Brilique jemali dvakrat na dan v 60-miligramskem oziroma 90-miligramskem odmerku.
English: In another main study, Brilique was compared with placebo (a dummy treatment) in over 21,000 adults who had a heart attack one to three years previously and were at high risk of an atherothrombotic event.
Slovenian: V drugi glavni študiji so zdravilo Brilique primerjali s placebom (zdravilom brez zdravilne učinkovine) pri več kot 21 000 odraslih, ki doživeli srčni infarkt eno do tri leta prej in pri katerih je obstajalo veliko tveganje za nastanek aterotrombotičnih dogodkov.
English: For the full list of restrictions with Brilique, see the package leaflet.
Slovenian: Za celoten seznam omejitev pri uporabi zdravila Brilique glejte navodilo za uporabo.
English: When the blood clots, this is due to cell fragments in the blood called platelets aggregating (sticking together).
Slovenian: Strjevanje krvi je posledica agregacije (zlepljanja) celičnih delcev v krvi, imenovanih trombociti.
English: How has Brilique been studied?
Slovenian: Kako je bilo zdravilo Brilique raziskano?
English: Brilique was shown to be beneficial to patients who have had a heart attack or unstable angina.
Slovenian: Zdravilo Brilique se je izkazalo kot koristno za bolnike z nestabilno angino ali po srčnem infarktu.
English: For the full list of all side effects reported with Brilique, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Brilique, glejte navodilo za uporabo.
English: In the second main study (in patients with a history of the heart attack), 7.8% of patients taking Brilique 60 mg twice a day had another heart attack, stroke or died from cardiovascular disease compared with 9.0% of patients taking placebo.
Slovenian: V drugi glavni študiji (pri bolnikih, ki so doživeli srčni infarkt ali kap) je 7,8 % bolnikov, ki so jemali zdravilo Brilique v 60-miligramskem odmerku dvakrat na dan, doživelo še en srčni infarkt ali kap ali pa so umrli zaradi srčno-žilne bolezni, v primerjavi z 9,0 % bolnikov, ki so jemali klopidogrel.
English: How does Brilique work?
Slovenian: Kako zdravilo Brilique deluje?
English: What is Brilique used for?
Slovenian: Za kaj se zdravilo Brilique uporablja?
English: For patients who have had a heart attack a year or more ago (but less than 2 years ago) and are at high risk of an atherothrombotic event, the dose of Brilique is one 60-mg tablet twice a day.
Slovenian: Odmerek pri bolnikih, ki so doživeli srčni infarkt pred enim letom ali več (vendar pred manj kot dvema letoma) in pri katerih obstaja veliko tveganje za nastanek aterotrombotičnih dogodkov, je ena
English: For patients with acute coronary syndrome, the starting dose of Brilique is two 90-mg tablets taken at once, followed by a regular dose of one 90-mg tablet twice a day.
Slovenian: Začetni odmerek zdravila Brilique pri bolnikih z akutnim koronarnim sindromom sta dve 90-miligramski tableti, ki ju bolnik vzame hkrati, sledi pa redni odmerek ene 90-miligramske tablete dvakrat na dan. Zdravljenje z zdravilom Brilique lahko traja eno leto, razen če zdravnik presodi, da ga je treba prekiniti prej.
English: What is Brilique?
Slovenian: Kaj je zdravilo Brilique?
English: How is Brilique used?
Slovenian: Kako se zdravilo Brilique uporablja?
English: Benefit regarding heart attack, stroke and death from a cardiovascular event has also been shown in patients who had a heart attack at least one year ago and have a high risk of an atherothrombotic event and a lower 60 mg dose twice daily dose is recommended for these patients.
Slovenian: Prav tako so bile pri bolnikih, pri so doživeli srčni infarkt pred najmanj enim letom in pri katerih obstaja veliko tveganje za nastanek aterotrombotičnih dogodkov opažene koristi v zvezi s srčnim infarktom, kapjo in smrtjo zaradi srčno-žilne bolezni.
English: Previously known as Zylagren
Slovenian: Prej znano kot Zylagren
English: The European Commission granted a marketing authorisation valid throughout the EU for Zylagren on 21 September 2009.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Zylagren, veljavno po vsej Evropski uniji, izdala 21. septembra 2009.
English: The full EPAR for Clopidogrel BGR can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za Clopidogrel BGR je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This is a summary of the European public assessment report (EPAR) for Clopidogrel BGR.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Clopidogrel BGR.
English: For more information about treatment with Clopidogrel BGR, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Clopidogrel BGR preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: The name of the medicine was changed to Clopidogrel BGR on 14 July 2014.
Slovenian: Ime zdravila je bilo 14. julija 2014 spremenjeno v Clopidogrel BGR.
English: The standard dose of Clopidogrel BGR is one 75 mg tablet once a day.
Slovenian: Standardni odmerek zdravila Clopidogrel BGR je ena 75-miligramska tableta enkrat na dan.
English: This means that Clopidogrel BGR is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix.
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Plavix.
English: Clopidogrel BGR is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries).
Slovenian: Zdravilo Clopidogrel BGR se uporablja pri odraslih za preprečevanje aterotrombotičnih dogodkov (težav, ki jih povzročajo krvni strdki in otrdelost krvnih žil).
English: Clopidogrel BGR can be given to the following groups of patients:
Slovenian: Zdravilo Clopidogrel BGR se lahko daje naslednjim skupinam bolnikov:
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Clopidogrel BGR.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: The Committee recommended that Clopidogrel BGR be given marketing authorisation.
Slovenian: Odbor je priporočil, da se za zdravilo Clopidogrel BGR izda dovoljenje za promet.
English: Because Clopidogrel BGR is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Slovenian: Ker je zdravilo Clopidogrel BGR generično zdravilo in je biološko enakovredno referenčnemu zdravilu, velja, da so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
English: The CHMP concluded that, in accordance with EU requirements, Clopidogrel BGR has been shown to have comparable quality and to be bioequivalent to Plavix.
Slovenian: CHMP je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Clopidogrel BGR primerljivo raven kakovosti kot zdravilo Plavix ter da mu je biološko enakovredno.
English: Clopidogrel BGR can be started between a few days and 35 days after the attack;
Slovenian: Zdravilo Clopidogrel BGR se lahko začne jemati od nekaj dni po napadu do 35 dni po njem;
English: Clopidogrel stops the platelets aggregating by blocking a substance called ADP from attaching to a special receptor on their surface.
Slovenian: Klopidogrel prepreči zlepljanje trombocitov tako, da snovi, imenovani ADP, preprečuje, da bi se vezala na posebne receptorje na njihovi površini.
English: • patients with peripheral arterial disease (problems with blood flow in the arteries);
Slovenian: • bolnikom s periferno arterijsko boleznijo (težavami s pretokom krvi v arterijah); Izdaja zdravila je le na recept.
English: What are the benefits and risks of Clopidogrel BGR?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Clopidogrel BGR?
English: Because Clopidogrel BGR is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
Slovenian: Ker je zdravilo Clopidogrel BGR generično zdravilo, so bile študije pri ljudeh omejene na preizkuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Plavix.
English: Clopidogrel BGR can be started between seven days and six months after the stroke;
Slovenian: Zdravilo Clopidogrel BGR se lahko začne jemati od sedem dni po napadu do šest mesecev po njem;
English: Clopidogrel BGR is a ‘generic medicine'.
Slovenian: Clopidogrel BGR je „generično zdravilo“.
English: Other information about Clopidogrel BGR
Slovenian: Druge informacije o zdravilu Clopidogrel BGR
English: Clopidogrel BGR is a medicine that contains the active substance clopidogrel.
Slovenian: Clopidogrel BGR je zdravilo, ki vsebuje zdravilno učinkovino klopidogrel.
English: The active substance in Clopidogrel BGR, clopidogrel, is an inhibitor of platelet aggregation.
Slovenian: Zdravilna učinkovina v zdravilu Clopidogrel BGR, klopidogrel, je zaviralec agregacije trombocitov.
English: Why has Clopidogrel BGR been approved?
Slovenian: Zakaj je bilo zdravilo Clopidogrel BGR odobreno?
English: What is Clopidogrel BGR?
Slovenian: Kaj je zdravilo Clopidogrel BGR?
English: What is Clopidogrel BGR used for?
Slovenian: Za kaj se zdravilo Clopidogrel BGR uporablja?
English: How has Clopidogrel BGR been studied?
Slovenian: Kako je bilo zdravilo Clopidogrel BGR raziskano?
English: How is Clopidogrel BGR used?
Slovenian: Kako se zdravilo Clopidogrel BGR uporablja?
English: How does Clopidogrel BGR work?
Slovenian: Kako zdravilo Clopidogrel BGR deluje?
English: Date of first authorisation: 8 March 2002 Date of latest renewal: 20 March 2007
Slovenian: Datum prve odobritve: 8. marec 2002 Datum zadnjega podaljšanja: 20. marec 2007
English: The available medical guidelines should also be taken into account.
Slovenian: Upoštevati je treba tudi razpoložljive medicinske smernice.
English: Additional information on MAS is provided below.
Slovenian: Dodatne informacije o MAS so na voljo spodaj.
English: The instructions for use and handling are given in section 6.6.
Slovenian: Navodila za uporabo in ravnanje so podana v poglavju 6.6.
English: RA: Adults
Slovenian: RA: Odrasli
English: Elderly population (≥ 65 years)
Slovenian: Starejša populacija (≥ 65 let)
English: A risk to the newborns/ infants cannot be excluded.
Slovenian: Tveganja za dojenega novorojenca/otroka ne moremo izključiti.
English: This might increase the risk of you getting an infection.
Slovenian: Zaradi tega se lahko poveča nevarnost, da boste dobili okužbo.
English: Pfizer Health AB Mariefredsvägen 37 SE-645 41 Strängnäs Sweden
Slovenian: Pfizer Health AB Mariefredsvägen 37 SE-645 41 Strängnäs Švedska
English: ISRs typically appear within 2 weeks of therapy and disappear within 4-6 weeks.
Slovenian: ISR se po navadi pojavijo v 2 tednih zdravljenja in izginejo v 4-6 tednih.
English: How do you give your injection?
Slovenian: Kako si daste injekcijo?
English: (~35 times the recommended dose in RA) over a 72 hour treatment period.
Slovenian: (~35-krat priporočeni odmerek pri RA) skozi 72 urno obdobje zdravljenja.
English: Pharmacokinetic parameters were not substantially different from healthy volunteers, other than a decrease in clearance of approximately 30% in comparison with data from a study with healthy volunteers.
Slovenian: Farmakokinetični parametri niso bili bistveno drugačni kot pri zdravih prostovoljcih, razen zmanjšanja očistka za približno 30 % v primerjavi s podatki iz študije z zdravimi prostovoljci.
English: The presence of these particles does not affect the quality of the product.
Slovenian: Prisotnost teh delcev ne vpliva na kakovost zdravila.
English: No dose adjustment is required based on age or gender.
Slovenian: Prilagoditev odmerka na podlagi starosti ali spola ni potrebna.
English: Do not warm Kineret in any other way (for example, do not warm it in a microwave or in hot water).
Slovenian: Ne ogrevajte zdravila Kineret kako drugače (ne grejte ga npr. v mikrovalovni pečici ali vroči vodi).
English: Distribution into the cerebrospinal fluid has been demonstrated.
Slovenian: Dokazana je bila porazdelitev v cerebrospinalno tekočino.
English: Anakinra is produced by DNA technology using the micro-organism E. coli.
Slovenian: Anakinra je izdelana s tehnologijo DNA z uporabo mikroorganizma E. coli.
English: Treatment with Kineret resulted in normalization of body temperature in 18 of 20 patients.
Slovenian: Zdravljenje z zdravilom Kineret je povzročilo normalizacijo telesne temperature pri 18 od 20 bolnikov.
English: No data are available on LDL or HDL cholesterol.
Slovenian: Podatki o LDL in HDL holesterolu niso na voljo.
English: This was not associated with any clinically significant effects on pharmacokinetics, efficacy, or safety.
Slovenian: To ni bilo povezano s klinično pomembnimi učinki na farmakokinetiko, učinkovitost ali varnost.
English: Do not reuse a syringe as this can cause infection.
Slovenian: Ne uporabljajte brizge ponovno, ker lahko to povzroči okužbo.
English: • A description of the signs of serious infections
Slovenian: • opis znakov resnih okužb.
English: Your doctor will tell you the dose that you need or whether you need a dose higher than 100 mg.
Slovenian: Zdravnik vam bo povedal, kateri odmerek potrebujete in če potrebujete odmerek, višji od 100 mg.
English: The majority (95%) of ISRs were reported as mild to moderate.
Slovenian: O večini (95 %) ISR so poročali kot o blagih do zmernih.
English: During the 5-year study 14 patients (32.6%) reported 24 serious events.
Slovenian: V 5-letni študiji je 14 bolnikov (32,6 %) poročalo o 24 resnih dogodkih.
English: This results in harmful effects leading to inflammation, causing the symptoms of the disease.
Slovenian: Zaradi tega pride do škodljivih učinkov, ki vodijo do vnetja in povzročijo simptome bolezni.
English: None of these patients had serious infections associated with the neutropenia.
Slovenian: Nobeden od teh bolnikov ni imel hudih okužb, povezanih z nevtropenijo.
English: Do not use Kineret if you think it has been frozen.
Slovenian: Ne uporabljajte zdravila Kineret, če mislite, da je bilo zamrznjeno.
English: Check the appearance of Kineret.
Slovenian: Preverite izgled zdravila Kineret.
English: Rheumatoid Arthritis (RA)
Slovenian: Revmatoidni artritis (RA)
English: The plasma concentration decreased with no discernible distribution phase and the terminal half-life ranged from 4 to 6 hours.
Slovenian: Koncentracije v plazmi so se zmanjšale brez opazne porazdelitvene faze in končni razpolovni čas je bil od 4 do 6 ur.
English: Posology and administration are the same as for adults 18 to 64 years of age.
Slovenian: Odmerjanje in način uporabe sta enaka kot pri odraslih, starih od 18 do 64 let.
English: However, you should contact your doctor, nurse or pharmacist if this does happen.
Slovenian: Vendar morate stopiti v stik s svojim zdravnikom, medicinsko sestro ali farmacevtom, če se to zgodi.
English: The main objectives of the programme are to provide information on the method of administration, raise awareness on the potential risk of macrophage activation syndrome (MAS) and on the potential risk of serious infections.
Slovenian: Glavni cilji programa so zagotovitev informacij o načinu uporabe, povečanje ozaveščenosti o možnem tveganju sindroma aktivacije makrofagov (MAS) in o možnem tveganju resnih okužb.
English: - CAPS: Kineret is not recommended for children younger than 8 months of age because there is no data in this age group.
Slovenian: - CAPS: Zdravilo Kineret ni priporočljivo za otroke, mlajše od 8 mesecev, ker ni podatkov za to starostno skupino.
English: The dose should be administered at approximately the same time each day.
Slovenian: Odmerek je treba dati vsak dan približno ob istem času.
English: One out of the 15 patients discontinued due to ISRs.
Slovenian: Eden od 15 bolnikov je prekinil zdravljenje zaradi ISR.
English: This could mean that the doses of some other medicines, e.g. warfarin or phenytoin, have to be adjusted.
Slovenian: To lahko pomeni, da bo treba prilagoditi odmerek nekaterih drugih zdravil, npr. varfarina ali fenitoina.
English: With the exception of infections and related symptoms that were more frequently reported in patients <2 years of age, the safety profile was similar in all paediatric age groups.
Slovenian: Razen okužb in povezanih simptomov, o katerih so pogosteje poročali pri bolnikih, starih do < 2 leti, je bil varnostni profil podoben v vseh pediatričnih starostnih skupinah.
English: - RA: Use of Kineret in children and adolescents with Rheumatoid Arthritis has not been fully investigated and therefore cannot be recommended.
Slovenian: - RA: Uporaba zdravila Kineret pri otrocih in mladostnikih z revmatoidnim artritisom ni bila povsem raziskana, zato je ni mogoče priporočiti.
English: What Kineret is and what it is used for
Slovenian: Kaj je zdravilo Kineret in za kaj ga uporabljamo
English: EU/1/02/203/005 - 1-pack EU/1/02/203/006 - 7-pack EU/1/02/203/007 - 28-pack
Slovenian: EU/1/02/203/005 - pakiranje po 1 EU/1/02/203/006 - pakiranje po 7 EU/1/02/203/007 - pakiranje po 28
English: No data are available in children under the age of 8 months.
Slovenian: Podatkov za otroke, mlajše od 8 mesecev, ni na voljo.
English: You will need to give yourself or your child an injection at the same time every day.
Slovenian: Injekcijo boste morali dati sebi ali svojemu otroku vsak dan ob istem času.
English: Accordingly, the decrease in clearance is most likely explained by a decrease in renal function in this population.
Slovenian: V skladu s tem se lahko zmanjšanje očistka najverjetneje pojasni z zmanjšanjem ledvične funkcije pri tej populaciji.
English: The risk for developing MAS is increased if you have an infection or if your Still's disease symptoms are poorly controlled.
Slovenian: Tveganje za razvoj MAS je večje, če imate okužbo ali če so vaši simptomi Stillove bolezni slabo nadzorovani.
English: For information on vaccinations see section 4.4.
Slovenian: Za informacije o vakcinacijah glejte poglavje 4.4.
English: When you start taking Kineret the chronic inflammation in your body will decrease.
Slovenian: Ko boste začeli jemati zdravilo Kineret, se bo kronično vnetje v vašem telesu zmanjšalo.
English: RA: The efficacy of Kineret in children with RA (JIA) aged 0 to 18 years has not been established.
Slovenian: RA: Učinkovitost zdravila Kineret pri otrocih z RA (JIA), starih od 0 do 18 let, ni bila dokazana.
English: Placebo treatment (n=213) resulted in a decrease of approximately 2.2% in total cholesterol levels at week 2 and 2.3% at week 24.
Slovenian: Zdravljenje s placebom (n = 213) je povzročilo zmanjšanje skupne ravni holesterola za približno 2,2 % v drugem tednu in 2,3 % v 24. tednu.
English: RA: No dose adjustment is required.
Slovenian: RA: Prilagoditev odmerka ni potrebna.
English: Because there is a higher incidence of infections in the elderly population in general, caution should be used in treating elderly patients.
Slovenian: Ker je v starejši populaciji na splošno večja incidenca okužb, morate biti pri zdravljenju starejših bolnikov previdni.
English: Upon start or end of Kineret treatment in patients on these types of medicinal products, it may be relevant to consider therapeutic monitoring of the effect or concentration of these products and the individual dose of the medicinal product may need to be adjusted.
Slovenian: Po začetku ali koncu zdravljenja z zdravilom Kineret pri bolnikih, ki se zdravijo s temi vrstami zdravil, je morda ustrezno razmisliti o terapevtskem spremljanju učinka ali koncentracije teh zdravil in morebitni potrebi po prilagoditvi odmerka zdravila.
English: It is important to tell your doctor if you are pregnant, if you think you may be pregnant or are planning to have a baby.
Slovenian: Pomembno je, da zdravniku poveste, da ste noseči, menite, da bi lahko bili noseči, ali če nameravate zanositi.
English: Cytokines are proteins made by your body that co-ordinate communication between cells and help control cell activity.
Slovenian: Citokini so beljakovine, ki jih izdeluje vaše telo za uravnavanje komuniciranja med celicami in kot pomoč pri kontroli celične aktivnost.
English: Maintenance dose in severe CAPS (MWS and NOMID/CINCA)
Slovenian: Vzdrževalni odmerek pri težkih oblikah CAPS (MWS in NOMID/CINCA)
English: • The importance of explaining the use of the syringe and correct injection technique to patients and/or caregivers
Slovenian: • pomembnost obrazložitve uporabe injekcijske brizge in pravilne tehnike injiciranja bolnikom in/ali skrbnikom,
English: Do not try to inject yourself if you have not been trained.
Slovenian: Ne poskušajte si sami dajati injekcij, če vas tega še niso naučili.
English: The most suitable places to inject yourself or your child are (See Figure D):
Slovenian: Najprimernejša mesta, kamor boste dali injekcijo sebi ali vašemu otroku (glejte sliko D)
English: Your doctor will discuss with you the potential risks of taking Kineret during pregnancy.
Slovenian: Vaš zdravnik vam bo razložil morebitna tveganja zaradi jemanja zdravila Kineret med nosečnostjo.
English: Turn the syringe so that the needle is now pointing downwards.
Slovenian: Obrnite brizgo tako, da je igla zdaj obrnjena navzdol.
English: Your doctor may decide that it would be more convenient for you to inject Kineret yourself.
Slovenian: Vaš zdravnik bo morda odločil, da bo za vas primerneje, če si boste zdravilo Kineret injicirali sami.
English: • the abdomen (except for the area around the navel)
Slovenian: • trebuh (razen predela okrog popka)
English: Immediately discard the needle cover.
Slovenian: Takoj zavrzite pokrovček igle.